Clinical trial results:
A SINGLE-ARM, MULTICENTER, PHASE II STUDY OF PANITUMUMAB IN COMBINATION WITH CAPECITABINE / OXALIPLATIN IN FIRST-LINE, WILD-TYPE K-RAS METASTATIC COLORECTAL CANCER PATIENTS

Summary

EudraCT number	2009-012655-26
Trial protocol	GR
Global end of trial date	26 August 2014

Results information

Result version number	v1 (current)
This version publication date	14 November 2018
First version publication date	14 November 2018

Trial information

Trial identification

Sponsor protocol code	HE 6A/09

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01215539
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Hellenic Cooperative Oncology Group
Sponsor organisation address	Hatzikonstandi 18, Athens, Greece, 11524
Public contact	Hellenic Cooperative Oncology Group, Hellenic Cooperative Oncology Group, hecogoff@otenet.gr
Scientific contact	Hellenic Cooperative Oncology Group, Hellenic Cooperative Oncology Group, hecogoff@otenet.gr

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	26 August 2014
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	26 August 2014
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To estimate the objective response rate in wild-type k-ras, metastatic colorectal cancer patients treated with panitumumab in combination with capecitabine/oxaliplatin as first-line therapy.

Protection of trial subjects:

This study was conducted in conformance with ICH GCP, all applicable laws and regulations. All participants were required to read and sign an Informed Consent Form.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	13 October 2010
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Greece: 78
Worldwide total number of subjects	78
EEA total number of subjects	78

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	37
From 65 to 84 years	41
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Participants were enrolled in the study from 13 October 2010 until 10 September 2013 from 12 sites in Greece.

Pre-assignment

Screening details:

All potentially eligible subjects underwent screening in order to confirm that all eligibility criteria were met prior to the first administration of the study treatment.

Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	Panitumumab+capecitabine+oxaliplatin

Arm description:

Panitumumab was administered by IV infusion on day 1 of each 3-week cycle prior to the administration of chemotherapy. The starting panitumumab dose was 9 mg/kg. Oxaliplatin 130 mg/m2 IV infusion over 2 hours on Day 1 of each cycle after the administration of panitumumab, capecitabine 2000 mg/m2 divided in two doses, orally, on Days 1 - 14.

Arm type	Experimental
Investigational medicinal product name	Panitumumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

The starting panitumumab dose was 9 mg/kg iv administration on day 1 of each 3-week cycle.

Number of subjects in period 1	Panitumumab+capecitabine+oxaliplatin
Started	78
Completed	45
Not completed	33
Physician decision	5
Consent withdrawn by subject	6
Adverse event, non-fatal	3
Death	4
Other	3
Progression	10
Moved to other hospital	2

Baseline characteristics

Reporting groups	
Reporting group title	Overall trial

Reporting group description: -

Reporting group values	Overall trial	Total	
Number of subjects	78	78	
Age categorical Units: Subjects			
Adults (18-64 years)	37	37	
From 65-84 years	41	41	
85 years and over	0	0	
Age continuous Units: years			
arithmetic mean	63.4		
full range (min-max)	30.1 to 80.9	-	
Gender categorical Units: Subjects			
Female	33	33	
Male	45	45	

End points

End points reporting groups

Reporting group title	Panitumumab+capecitabine+oxaliplatin

Reporting group description:

Panitumumab was administered by IV infusion on day 1 of each 3-week cycle prior to the administration of chemotherapy. The starting panitumumab dose was 9 mg/kg. Oxaliplatin 130 mg/m2 IV infusion over 2 hours on Day 1 of each cycle after the administration of panitumumab, capecitabine 2000 mg/m2 divided in two doses, orally, on Days 1 - 14.

Primary: Objective Response Rate

End point title	Objective Response Rate[1]

End point description:

Response was centrally assessed using RECIST criteria.An objective response was defined as either a complete or a partial response.

End point type	Primary

End point timeframe:

Tumor response was assessed every 6 weeks through week 18 and every 3 months thereafter, until disease progression

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The percentage of patients that achieved a complete or partial response out of the total number of enrolled patients is provided. No comparisons were performed since this was a single-arm study.

End point values	Panitumumab+capecitabine+oxaliplatin			
Subject group type	Reporting group			
Number of subjects analysed	78			
Units: percentage of patients				
number (not applicable)	44.9			

Statistical analyses

No statistical analyses for this end point

Secondary: Progression-Free Survival

End point title	Progression-Free Survival

End point description:

Progression-free survival was defined as the time from the date of enrollment to the date of documented disease progression, death or last contact. Deaths without a documented progression were treated as events at the time of death for the PFS analysis.

End point type	Secondary

End point timeframe:

Tumor response was assessed every 6 weeks through week 18 and every 3 months thereafter, until disease progression.

End point values	Panitumumab+ capecitabine+oxaliplatin			
Subject group type	Reporting group			
Number of subjects analysed	78			
Units: months				
median (confidence interval 95%)	8.1 (6.5 to 9.9)			

Attachments (see zip file)	Kaplan-meier with respect to PFS/PFS_HE6A09.png

Statistical analyses

No statistical analyses for this end point

Secondary: Safety profile

End point title	Safety profile

End point description:

End point type	Secondary

End point timeframe:

Adverse Events of all participants were recorded and assessed upon signature of the Informed Consent Form, until 30 days after the last administration of study treatment.

End point values	Panitumumab+ capecitabine+oxaliplatin			
Subject group type	Reporting group			
Number of subjects analysed	78			
Units: number of patients				
Any adverse event	76			
Adverse event grade≥3	54			
Adverse event grade≥4	12			
Fatal adverse events	6			
Serious adverse events	27			

Statistical analyses

No statistical analyses for this end point

Secondary: Overall survival

End point title	Overall survival

End point description:

Overall survival was defined as the time from enrollment to the date of death or last contact. Alive patients were censored at the date of their last contact.

End point type	Secondary

End point timeframe:

The median follow-up time was 12.8 months (range 0-39).

End point values	Panitumumab+ capecitabine+oxaliplatin			
Subject group type	Reporting group			
Number of subjects analysed	78			
Units: months				
median (confidence interval 95%)	23.2 (18.0 to 28.8)			

Attachments (see zip file)	Kaplan-meier curve with respect to OS/OS_HE6A09.png

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse Events of all participants were recorded and assessed upon signature of the Informed Consent Form, until 30 days after the last administration of study treatment.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	12.1

Reporting groups

Reporting group title	Panitumumab+capecitabine+oxaliplatin

Reporting group description:

Panitumumab was administered by IV infusion on day 1 of each 3-week cycle prior to the administration of chemotherapy. The starting panitumumab dose was 9 mg/kg. Oxaliplatin 130 mg/m2 IV infusion over 2 hours on Day 1 of each cycle after the administration of panitumumab, capecitabine 2000 mg/m2 divided in two doses, orally, on Days 1 - 14.

Serious adverse events	Panitumumab+capecitabine+oxaliplatin		
Total subjects affected by serious adverse events			
subjects affected / exposed	27 / 78 (34.62%)		
number of deaths (all causes)	26		
number of deaths resulting from adverse events	6		
Investigations			
Hyperbilirubinaemia			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Neutropenia			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Thrombocytopenia			
subjects affected / exposed	2 / 78 (2.56%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Deep vein thrombosis			

subjects affected / exposed	2 / 78 (2.56%)			
occurrences causally related to treatment / all	1 / 2			
deaths causally related to treatment / all	1 / 1			
Phlebitis superficial				
subjects affected / exposed	1 / 78 (1.28%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Ischaemic stroke				
subjects affected / exposed	1 / 78 (1.28%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	1 / 1			
Cardiac disorders				
Cardiac arrest				
subjects affected / exposed	1 / 78 (1.28%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	1 / 1			
Nervous system disorders				
Depressed level of consciousness	Additional description: Somnolence			
subjects affected / exposed	1 / 78 (1.28%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	1 / 1			
Neuropathy				
subjects affected / exposed	1 / 78 (1.28%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Neuropathy sensory				
subjects affected / exposed	1 / 78 (1.28%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Blood and lymphatic system disorders				
Anaemia				
subjects affected / exposed	1 / 78 (1.28%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			

General disorders and administration site conditions			
Catheter site thrombosis			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Sudden death	Additional description: Cause unknown		
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	1 / 1		
Immune system disorders			
Allergic reaction			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	6 / 78 (7.69%)		
occurrences causally related to treatment / all	6 / 6		
deaths causally related to treatment / all	0 / 0		
Ileus			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	1 / 1		
Vomiting			
subjects affected / exposed	3 / 78 (3.85%)		
occurrences causally related to treatment / all	3 / 3		
deaths causally related to treatment / all	0 / 0		
Abdominal pain			
subjects affected / exposed	3 / 78 (3.85%)		
occurrences causally related to treatment / all	2 / 3		
deaths causally related to treatment / all	0 / 0		
Intestinal perforation			

subjects affected / exposed	1 / 78 (1.28%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Rectal haemorrhage				
subjects affected / exposed	1 / 78 (1.28%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Intestinal obstruction				
subjects affected / exposed	1 / 78 (1.28%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Respiratory, thoracic and mediastinal disorders				
Pulmonary embolism				
subjects affected / exposed	2 / 78 (2.56%)			
occurrences causally related to treatment / all	2 / 2			
deaths causally related to treatment / all	0 / 0			
Dyspnoea				
subjects affected / exposed	1 / 78 (1.28%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	1 / 1			
Chronic obstructive pulmonary disease	Additional description: Exacerbation of Chronic Obstructive Pulmonary Disease			
subjects affected / exposed	1 / 78 (1.28%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	1 / 1			
Infections and infestations				
Infection				
subjects affected / exposed	2 / 78 (2.56%)			
occurrences causally related to treatment / all	2 / 2			
deaths causally related to treatment / all	0 / 0			
Lung infection				
subjects affected / exposed	1 / 78 (1.28%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			

Infectious colitis			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Urinary tract infection			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Diverticulitis			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Hypokalaemia			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Panitumumab+capecitabine+oxaliplatin		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	76 / 78 (97.44%)		
Vascular disorders			
Phlebitis			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	26 / 78 (33.33%)		
occurrences (all)	36		
Insomnia			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Fever			

subjects affected / exposed	3 / 78 (3.85%)		
occurrences (all)	4		
Edema head and neck			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Edema limbs			
subjects affected / exposed	4 / 78 (5.13%)		
occurrences (all)	4		
Flu like symptomes			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Pain			
subjects affected / exposed	10 / 78 (12.82%)		
occurrences (all)	11		
Immune system disorders			
Allergic reaction			
subjects affected / exposed	5 / 78 (6.41%)		
occurrences (all)	9		
Immune system disorder	Additional description: Allergy-Dermatology-Skin		
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Respiratory, thoracic and mediastinal disorders			
Hemorrhage pulmonary			
subjects affected / exposed	3 / 78 (3.85%)		
occurrences (all)	4		
Bronchospasm			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Cough			
subjects affected / exposed	4 / 78 (5.13%)		
occurrences (all)	4		
Dyspnoea			
subjects affected / exposed	4 / 78 (5.13%)		
occurrences (all)	5		
Voice alteration			

subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Psychiatric disorders			
Confusional state			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Personality change			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Investigations			
Weight decreased			
subjects affected / exposed	8 / 78 (10.26%)		
occurrences (all)	8		
International normalised ratio increased			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Activated partial thromboplastin time prolonged			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Alanine aminotransferase increased			
subjects affected / exposed	19 / 78 (24.36%)		
occurrences (all)	33		
Aspartate aminotransferase increased			
subjects affected / exposed	36 / 78 (46.15%)		
occurrences (all)	67		
Alkaline phosphatase increased			
subjects affected / exposed	29 / 78 (37.18%)		
occurrences (all)	38		
Amylase increased			
subjects affected / exposed	2 / 78 (2.56%)		
occurrences (all)	3		
Blood bilirubin increased			
subjects affected / exposed	20 / 78 (25.64%)		
occurrences (all)	31		
Hypercholesterolaemia			

subjects affected / exposed	4 / 78 (5.13%)			
occurrences (all)	4			
Creatinine increased				
subjects affected / exposed	2 / 78 (2.56%)			
occurrences (all)	2			
Gamma-glutamyltransferase increased				
subjects affected / exposed	28 / 78 (35.90%)			
occurrences (all)	33			
Hyperkalaemia				
subjects affected / exposed	7 / 78 (8.97%)			
occurrences (all)	8			
Hypermagnesaemia				
subjects affected / exposed	9 / 78 (11.54%)			
occurrences (all)	11			
Hypernatraemia				
subjects affected / exposed	1 / 78 (1.28%)			
occurrences (all)	1			
Hypertriglyceridaemia				
subjects affected / exposed	2 / 78 (2.56%)			
occurrences (all)	2			
Hyperuricaemia				
subjects affected / exposed	3 / 78 (3.85%)			
occurrences (all)	4			
Hypoalbuminaemia				
subjects affected / exposed	24 / 78 (30.77%)			
occurrences (all)	29			
Hypocalcaemia				
subjects affected / exposed	12 / 78 (15.38%)			
occurrences (all)	14			
Hypokalaemia				
subjects affected / exposed	22 / 78 (28.21%)			
occurrences (all)	37			
Hypomagnesaemia				
subjects affected / exposed	24 / 78 (30.77%)			
occurrences (all)	33			

Hyponatraemia			
subjects affected / exposed	10 / 78 (12.82%)		
occurrences (all)	15		
Hypophosphataemia			
subjects affected / exposed	4 / 78 (5.13%)		
occurrences (all)	6		
Blood lactate dehydrogenase increased			
subjects affected / exposed	20 / 78 (25.64%)		
occurrences (all)	35		
Blood urea increased			
subjects affected / exposed	2 / 78 (2.56%)		
occurrences (all)	2		
Injury, poisoning and procedural complications			
Vascular access complication			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Cardiac disorders			
Hypotension			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Nervous system disorders			
Dysgeusia			
subjects affected / exposed	5 / 78 (6.41%)		
occurrences (all)	6		
Dizziness			
subjects affected / exposed	2 / 78 (2.56%)		
occurrences (all)	2		
Mood altered			
subjects affected / exposed	2 / 78 (2.56%)		
occurrences (all)	2		
Vertigo			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Peripheral motor neuropathy			
subjects affected / exposed	2 / 78 (2.56%)		
occurrences (all)	2		

Peripheral sensory neuropathy			
subjects affected / exposed	35 / 78 (44.87%)		
occurrences (all)	53		
Neuropathy cranial			
alternative dictionary used: CTCAE 3			
subjects affected / exposed	3 / 78 (3.85%)		
occurrences (all)	4		
Speech disorder			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	28 / 78 (35.90%)		
occurrences (all)	45		
Leukopenia			
subjects affected / exposed	26 / 78 (33.33%)		
occurrences (all)	46		
Neutropenia			
subjects affected / exposed	24 / 78 (30.77%)		
occurrences (all)	44		
Thrombocytopenia			
subjects affected / exposed	26 / 78 (33.33%)		
occurrences (all)	51		
Ear and labyrinth disorders			
Ear and labyrinth disorder- other	Additional description: Partial temporary hearing loss		
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Eye disorders			
Dry eye			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Ocular surface disease			
subjects affected / exposed	4 / 78 (5.13%)		
occurrences (all)	4		
Gastrointestinal disorders			

Constipation				
subjects affected / exposed	11 / 78 (14.10%)			
occurrences (all)	13			
Diarrhoea				
subjects affected / exposed	34 / 78 (43.59%)			
occurrences (all)	60			
Flatulence				
subjects affected / exposed	1 / 78 (1.28%)			
occurrences (all)	1			
Dry mouth				
subjects affected / exposed	2 / 78 (2.56%)			
occurrences (all)	2			
Dysphagia				
subjects affected / exposed	4 / 78 (5.13%)			
occurrences (all)	4			
Stomatitis				
subjects affected / exposed	10 / 78 (12.82%)			
occurrences (all)	13			
Nausea				
subjects affected / exposed	17 / 78 (21.79%)			
occurrences (all)	26			
Vomiting				
subjects affected / exposed	16 / 78 (20.51%)			
occurrences (all)	26			
Gastrointestinal pain				
subjects affected / exposed	1 / 78 (1.28%)			
occurrences (all)	1			
Abdominal distension				
subjects affected / exposed	1 / 78 (1.28%)			
occurrences (all)	1			
Esophagitis				
subjects affected / exposed	1 / 78 (1.28%)			
occurrences (all)	1			
Hemorrhage gastrointestinal				
subjects affected / exposed	1 / 78 (1.28%)			
occurrences (all)	1			

Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	13 / 78 (16.67%)		
occurrences (all)	13		
Cheilitis			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Skin disorder			
subjects affected / exposed	6 / 78 (7.69%)		
occurrences (all)	6		
Dry skin			
subjects affected / exposed	6 / 78 (7.69%)		
occurrences (all)	6		
Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	20 / 78 (25.64%)		
occurrences (all)	23		
Nail disorder			
subjects affected / exposed	4 / 78 (5.13%)		
occurrences (all)	4		
Photosensitivity reaction			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Pruritus			
subjects affected / exposed	4 / 78 (5.13%)		
occurrences (all)	4		
Rash			
subjects affected / exposed	56 / 78 (71.79%)		
occurrences (all)	63		
Hyperhidrosis			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Hair growth rate abnormal			
subjects affected / exposed	2 / 78 (2.56%)		
occurrences (all)	2		
Subcutaneous abscess			

subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Renal and urinary disorders			
Hematuria			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Hemorrhage GU			
alternative dictionary used: CTCAE 3			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Infections and infestations			
Infections and infestations- Other specify			
subjects affected / exposed	4 / 78 (5.13%)		
occurrences (all)	5		
Lower respiratory tract infection			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Upper respiratory tract infection			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Viral infection			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Diverticulitis			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Nail infection			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Herpes virus infection			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Metabolism and nutrition disorders			
Anorexia			
subjects affected / exposed	19 / 78 (24.36%)		
occurrences (all)	24		

Hyperglycemia subjects affected / exposed occurrences (all)	32 / 78 (41.03%) 65		
Hypoglycaemia subjects affected / exposed occurrences (all)	1 / 78 (1.28%) 1		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported